As an Independent Consultant, specializing in the development and registration of New Chemical Entities (NCE) from pre-clinical, early to late stage development leading to registration state; I have consulted to both Pharmaceutical and Biotech companies, Contract Research Organizations (CROs), Universities and Financial Institutions.
Key areas in regulatory affairs and drug development include CNS (specifically in Parkinson disease, Alzheimer’s disease, depression, schizophrenia, and neuropathic pain), oncology, diabetes, rheumatology, anti-inflammatories and anti-infectives.